Al­ler­gan and Merz set­tle more Alzheimer's drug pay-for-de­lay al­le­ga­tions for $54M

Al­ler­gan and Merz Phar­ma yes­ter­day un­veiled a $54.4 mil­lion set­tle­ment with a New York la­bor union for po­lice of­fi­cers to dis­miss their suit (with­out any ad­mis­sion of guilt) re­lat­ed to the com­pa­nies’ clamp­ing down on about a dozen gener­ic com­peti­tors for the Alzheimer’s drug Na­men­da.

First ap­proved in 2003, For­est Lab­o­ra­to­ries (ac­quired by Ac­tavis in 2014, which then be­came Al­ler­gan) halt­ed Na­men­da gener­ic com­peti­tors un­til mid-2015, even as FDA be­gan ful­ly ap­prov­ing the gener­ics in 2010. The dozen gener­ic de­lays were due to so-called pay-for-de­lay deals, the union al­leged in a com­plaint filed in 2015 in the South­ern Dis­trict of New York.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN